Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)
Condition(s):Chronic Kidney Disease Stage 3 and 4Last Updated:July 2, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Chronic Kidney Disease Stage 3 and 4Last Updated:July 2, 2018Completed
Condition(s):HealthyLast Updated:December 23, 2014Completed
Condition(s):Chronic Kidney Disease; Endothelial Dysfunction; Inflammation; HypertensionLast Updated:June 3, 2009Completed
Condition(s):Secondary Hyperparathyroidism; DialysisLast Updated:October 25, 2011Completed
Condition(s):Fabry Disease; ProteinuriaLast Updated:March 18, 2014Completed
Condition(s):Chronic Kidney DiseaseLast Updated:April 28, 2014Completed
Condition(s):Secondary Hyperparathyroidism Due to Renal CausesLast Updated:November 19, 2018Completed
Condition(s):AnemiaLast Updated:August 24, 2022Recruiting
Condition(s):Secondary Hyperparathyroidism; HemodialysisLast Updated:April 19, 2011Completed
Condition(s):Diabetic Nephropathy; Chronic Kidney DiseaseLast Updated:January 20, 2012Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.